HSV-2 vaccine shows significant clinical symptoms & viral shedding reductions at 6 months

(Linnden Communications) Updated Phase 1/2a GEN-003 results, a vaccine candidate under development for the treatment of herpes simplex virus type 2 infection, showed the vaccine generated highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose. Genocea, a company pioneering novel T cell vaccines and immunotherapies, reported the results from the ongoing trial as an oral presentation at the World Vaccine Congress.
Source: EurekAlert! - Social and Behavioral Science - Category: Global & Universal Source Type: news